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HEMATOPOIESIS AND STEM CELLS
Expression of angiotensin-converting enzyme (CD143) identifies and regulates
primitive hemangioblasts derived from human pluripotent stem cells
Elias T. Zambidis,1,2 Tea Soon Park,3 Wayne Yu,2 Ada Tam,1 Michal Levine,1 Xuan Yuan,1,2 Marina Pryzhkova,1 and
Bruno Pe´ault3
1Institute of Cell Engineering, Stem Cell Program, Johns Hopkins University School of Medicine, and 2Division of Pediatric Oncology, Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; and 3Stem Cell Research Center, Department of Pediatrics, McGowan Institute for
Regenerative Medicine, University of Pittsburgh School of Medicine, PA
We report that angiotensin-converting en-
zyme (ACE), a critical physiologic regula-
tor of blood pressure, angiogenesis, and
inflammation, is a novel marker for identi-
fying hemangioblasts differentiating from
human embryonic stem cells (hESC). We
demonstrate that ACECD45CD34/ he-
mangioblasts are common yolk sac (YS)–
like progenitors for not only endothelium
but also both primitive and definitive hu-
man lymphohematopoietic cells. Throm-
bopoietin and basic fibroblast growth fac-
tor are identified as critical factors for the
proliferation of human hemangioblasts.
The developmental sequence of human
embryoid body hematopoiesis is remark-
ably congruent to the timeline of normal
human YS development, which occurs
during weeks 2 to 6 of human gestation.
Furthermore, ACE and the renin-
angiotensin system (RAS) directly regu-
late hemangioblast expansion and differ-
entiation via signaling through the
angiotensin II receptors AGTR1 and
AGTR2. ACE enzymatic activity is re-
quired for hemangioblast expansion, and
differentiation toward either endothelium
or multipotent hematopoietic progenitors
is dramatically augmented after manipula-
tion of angiotensin II signaling with either
AGTR1- or AGTR2-specific inhibitors. The
RAS can therefore be exploited to direct
the hematopoietic or endothelial fate of
hESC-derived hemangioblasts, thus pro-
viding novel opportunities for human tis-
sue engineering. Moreover, the initial
events of human hematoendotheliogen-
esis can be delineated in a manner previ-
ously impossible because of inaccessibil-
ity to early human embryonic tissues.
(Blood. 2008;112:3601-3614)
Introduction
Human hematopoiesis initiates during the third week of develop-
ment with formation of yolk sac (YS) blood islands derived from
extraembryonic mesoderm.1,2 The YS generates primarily nucle-
ated primitive erythroblasts that express predominantly embryonic
hemoglobins (eg, ε22, Gower I; 2ε2, Gower II; and 22,
Portland), and primitive macrophages.3 After the onset of circula-
tion at approximately 21 days of embryonic development, YS
blood cells continue to circulate in embryonic blood, but the fetal
liver (FL) eventually replaces the YS as the main hematopoietic
organ beginning at 5 to 6 weeks. FL hematopoiesis is dominated by
adult-type definitive erythrocytes (enucleated, macrocytic) express-
ing abundant fetal (HbF; 22), adult (HbA; 22) hemoglobins,
but limited embryonic hemoglobins.4-6 The FL also produces rare
megakaryocytes, granulocytes, macrophages, lymphocytes, and
blast cells.7 Definitive erythroid, myeloid, megakaryocytic, natural
killer-B (NK-B) lymphoid, and multipotent progenitors, with
limited long-term engraftment potential, are briefly detected during
the late YS (eg, 4-5 weeks) stage, before fetal liver hematopoiesis,
in both mice and humans.2,8-9 The ephemeral nature of definitive-
type YS hematopoiesis suggests a gradual yolk sac-fetal liver
transition.1 Indeed, the classic embryonic3 fetal3 adult globin
switch in early erythrocytes occurs sequentially over time and
probably in the same clonal lineage. For example, late YS
erythrocytes (ie, 6 weeks), produce strictly embryonic globins in
vivo but, after in vitro culture, produce erythroid bursts that
simultaneously coexpress the entire spectrum of embryonic, fetal,
and adult hemoglobins.5,10 In contrast to the limited nature of YS
hematopoiesis, the intraembryonic truncal mesoderm of the aorta-
gonad-mesonephros (AGM) region generates self-renewing hema-
topoietic stem cells (HSCs) that ultimately colonize the FL,
thymus, and bone marrow11-15 and provide the lifetime supply of
adult blood cells.
In both mice and humans, there is compelling evidence that
both YS and AGM-derived HSCs arise from a bipotential
hemangioblast that generates hematopoietic and endothelial
cells.16-22 The nature of this progenitor remains elusive, how-
ever, in part because reliable markers for this cell are lacking,
and early human embryonic tissue is difficult to obtain. The
efficient derivation and expansion of such hemangioblasts from
human pluripotent stem cells has potentially great impact,
because it may lead to strategies for treating a multitude of
hematologic and vasculodestructive disorders.
We and others have described methods for the hematopoietic
differentiation of human embryonic stem cells (hESCs), including
the derivation of human embryoid body (hEB) progenitors with
hemangioblastic potential.23-29 Our group first described a hESC
model that recapitulates the yolk sac stages of human embryonic
hematoendothelial development.25 Hematopoietic activity was
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shown to arise in hEB cells from CD45 mesodermal-hemato-
endothelial (MHE) progenitors that give rise to hematopoietic blast
colonies, and 2 sequential YS-like primitive and definitive hemato-
poietic waves. Although we delineated the kinetics of hEB
differentiation for the emergence of a putative common hemangio-
blastic progenitor responsible for these 2 waves, we did not
validate this stem-progenitor cell in a clonal manner. In contrast to
murine experimental systems, clonal characterization of a human
hemangioblast has been hindered by inefficient hematopoietic
differentiation of hESC, lack of an accurate prospective hemangio-
blast surface marker, and absence of a quantitative hemangioblast
assay (blast colony-forming cell: BL-CFC assay), although one
group recently described such an assay.28 Furthermore, although
KDR/flk-1 (VEGFR2) is a cell surface marker of populations
containing hemangioblasts in the mouse,30-32 it has proven less
reliable in specifying rare hemangioblasts in human tissues,
because it is widely expressed (10%-40% hEB cells) during
hESC differentiation and normal embryonic development.2,19,28
Using a monoclonal antibody (BB9) specific for the somatic isoform
of surface angiotensin-converting enzyme (ACE/CD143), a primitive
subset of CD34 multilineage, NOD-SCID mouse-engrafting HSC was
identified in adult bone marrow, mobilized peripheral blood, and
umbilical cord blood.33,34 Moreover, BB9/ACE expression identified
emerging hematopoietic cells from both CD34 and CD34 areas of
human YS, intraembryonic splanchnopleura, and hemogenic endothe-
lium of the AGM region and FL. The embryonic pattern of human ACE
expression is consistent with a dorsal emigration of ACECD34
hemangioblasts from the para-aortic splanchnopleura, and subsequent
colonization of the ventral aspect of the dorsal aorta to give rise to
CD34 hemogenic endothelial cells. The identification of surface ACE
on these primitive progenitors raises the possibility that the protean
renin-angiotensin system (RAS) plays an unrecognized role in regulat-
ing the earliest stages of human hemato-endothelial differentiation, as it
does in avian embryos.35
In the present studies, we tested the hypothesis that ACE
expression in differentiating hESCs typifies emerging human
embryonic hemangioblasts. We present serum-free (SF) culture
methods for the generation and prospective isolation of ACE
hemangioblasts and demonstrate that these cells represent common
clonogenic progenitors for YS-like primitive and definitive hemato-
poieses as well as endothelium. More importantly, we demonstrate
for the first time that the RAS axis (which is known to regulate
blood pressure, inflammation, and angiogenesis in adults) is a
pivotal regulator of human hemangioblast differentiation. We show
that the 2 main angiotensin II–binding receptors, AGTR1 and
AGTR2, are expressed on human hemangioblasts, and importantly,
that differentiation into either hematopoietic or endothelial progeni-
tors can be influenced by modulating the signaling through these
receptors. These data advance our understanding of the earliest
steps in human developmental hematopoiesis and may also assist
the design of regenerative medicine approaches that aim to use
hESC-derived hemangioblasts.
Methods
SF hEB differentiation
hESC lines H1, H9, and ES03 (National Institutes of Health [NIH] Human
Embryonic Stem Cell Registry codes WA01, WA09, and ES03) were
maintained on irradiated primary murine embryonic feeders, and hEBs
were formed from hESC clumps in semisolid, serum-supplemented me-
dium, exactly as previously described.25 Twenty-four hours after hESC
plating (day 2), simple hEBs were harvested, washed, resuspended in PBS
in 50-mL conical tubes, and collected by gentle gravity settling for 2 to
3 minutes. hEBs were resuspended into 6-well ultranonadherent plates
(Corning Life Sciences, Acton, MA) at approximately 100-200 hEB/mL in
SF liquid differentiation medium (SF LDM), consisting of serum-free
expansion medium (SFEM; StemCell Technologies, Vancouver, BC) supple-
mented with 50 g/mL ascorbic acid (Sigma-Aldrich, St Louis, MO),
1% EX-CYTE (Millipore, Billerica, MA), 0.5% insulin/transferrin/
selenium (Invitrogen, Carlsbad, CA), 3% PFHM-II (Invitrogen), and
penicillin/streptomycin (Sigma-Aldrich). Various combinations of human
growth factors (all from R&D Systems [Minneapolis, MN], Peprotech
[Rocky Hill, NJ], or Invitrogen) were added directly into SF LDM at 2 to
20 days of hEB development: BMP4 (50 ng/mL), vascular endothelial
growth factor (VEGF; 50 ng/mL), FGF1 (50 ng/mL  5 g/mL heparan
sulfate; Sigma), FGF2 (50 ng/mL  5 g/mL heparan sulfate). hEB
cultures were fed by hemidepletion and replacement of medium every
2-3 days with fresh SF LDM and GFs. In general, optimal, robust
hematopoietic differentiation relied on (1) a uniform size of hEBs initially
formed from hESC clumps and (2) passage number of hESC less than 50.
To expand hEB-derived hematopoietic progenitors, enzymatically
digested (Accutase; Sigma-Aldrich) day 9-10 hEB clumps, differenti-
ated as described above, were transferred into SF LDM and allowed to
adhere to gelatinized tissue culture plates. SF cultures were supple-
mented with various hematopoietic inductive factors including: BMP4
(50 ng/mL), stem cell factor (SCF; 50 ng/mL), Flt3L (50 ng/mL),
thrombopoietin (TPO; 50 ng/mL), granulocyte macrophage–colony-
stimulating factor (GM-CSF; 50 ng/mL), granulocyte–colony-stimulat-
ing factor (G-CSF; 50 ng/mL), interleukin-3 (IL-3; 20 ng/mL), IL-6 (20
ng/mL), VEGF (20 ng/mL), erythropoietin (EPO; 2 units/mL), FGF1 (10
ng/mL), and FGF2 (10 ng/mL).
SF clonogenic assays for hematopoietic and hemangioblastic
colony-forming cells
hEBs were harvested from SF LDM at various time points, enzymatically
disaggregated (Accutase; Sigma-Aldrich) into single-cell suspensions, and
passed through a 70-m strainer. Aliquots of viable hEB cells (which
ranged between 40% and 75%) were enumerated by fluorescence-activated
cell sorting (FACS) analysis before plating. hEB cells were plated
(1.0-2.0 	 105 viable cells/mL) in duplicate/triplicate CFC dishes (NUNC
A/S, Roskilde, Denmark), and assayed in humidified chambers for the
presence of hematopoietic colony-forming cell (CFC) progenitors in 2 mL
SF methylcellulose-based medium (StemCell Technologies) containing
SCF (50 ng/mL), EPO (3 U/mL), GM-CSF (50 ng/mL), G-CSF (50 ng/mL),
IL-3 (20 ng/mL), and IL-6 (20 ng/mL), which was supplemented with 0.5%
EX-CYTE (Millipore Bioscience Research Reagents, Temecula, CA).
Fourteen to 21 days later, colonies were scored, and plucked for cytospin or
quantitative reverse transcription polymerase chain reaction (qRT-PCR)
analysis. Hematopoietic colony morphology was scored by criteria as
previously described.25 Positive control sibling CFC assays for generating
adult definitive-type colonies were also prepared with approximately
1000 CD34 FACS-enriched cord blood (CB) cells, and plated into 2 mL
semisolid H4436 medium.
BL-CFC (hemangioblast) cultures were grown at 37°C in humidified,
plastic-wrapped (hypoxic), ultranonadherent plates (Corning Life Science),
in 2 mL SF methylcellulose base medium (StemCell Technologies),
supplemented with 50 g/mL ascorbic acid (Sigma-Aldrich), 1% EX-
CYTE, 0.5% insulin/transferrin/selenium (Invitrogen), and 3% PFHM-II
(Invitrogen). Suspensions of single hEB cells at different time points of
differentiation were prepared with Accutase digestion, and passaged
through a 70-m strainer. Viability of enzyme-digested hEB cell suspen-
sions was determined by flow cytometry using ViaProbe (BD Biosciences,
San Jose, CA) staining, and 1 to 1.5 	 105/mL viable hEB cells were plated
in 2 mL SF methylcellulose supplemented with BMP4 (50 ng/mL), VEGF
(50 ng/mL), FGF2 (50 ng/mL), heparan sulfate (5 g/mL; Sigma-Aldrich),
TPO (50 ng/mL), IL-6 (50 ng/mL), with or without additional growth
factors (GFs; eg, 2 U/mL EPO and 50 ng/mL SCF), as described in the text.
Blast colonies formed (per 106 viable hEB cells originally plated) were
enumerated 5 to 6 days after plating.
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Hemangioblastic CFC potential of single FACS-sorted hEB cells was
directly determined on fibronectin-coated (10 g/mL; Invitrogen) CFC
dishes placed in humidified chambers. Purified cells were evaluated and
enumerated for purity and viability by postsort FACS analysis; the
corrected percentage viability was determined before plating. Five to
20 	103 single, sorted viable cells in 2 mL of SF H4436 methylcellulose
medium (StemCell Technologies) already containing SCF (50 ng/mL), EPO
(3 U/mL), GM-CSF (50 ng/mL), G-CSF (50 ng/mL), IL-3 (20 ng/mL), and
IL-6 (20 ng/mL). This semisolid medium was further supplemented with
BMP4 (50 ng/mL), VEGF (50 ng/mL), Flt3 ligand (50 ng/mL), TPO
(50 ng/mL), IGF-I (50 ng/mL), FGF2 (25 ng/mL) plus 5 g/mL heparan
sulfate, 0.5% EX-CYTE, and 1% PFHM-II. Under these conditions,
primitive-type hematoendothelial colonies expanded robustly from single
adherent cells. Multilineage colonies were enumerated after 10 to 14 days
and were composed of nonadherent erythromyeloid cells, intermixed with
adherent Dil-acetylated low-density lipoprotein (LDL)–avid, CD31, vas-
cular endothelial (VE)–cadherin plus endothelial cells.
Additional details are available on the Blood website; see the Supplemen-
tal Materials link at the top of the online article.
Hematopoietic differentiation cultures
Secondary plating of blast colonies was done after expansion for
5 to 6 days after plating from various time points of hEB differentiation.
Individual blast colonies were plucked from methylcellulose medium with
a pipet, using inverted microscopic guidance. Blast colony cells were
disaggregated and directly replated for secondary hemangioblastic differen-
tiation on fibronectin-coated 24-well dishes in 0.5 mL SF H4436 methylcel-
lulose supplemented with the full complement of hematoendothelial GFs,
exactly as described above. Primitive-type, nonadherent secondary hemato-
poietic colonies were enumerated, collected for FACS or qRT-PCR
analysis, or gently aspirated away after 7-10 days for analysis of adherent
cells by in situ immunofluorescence.
To evaluate definitive hematopoietic potential, FACS-purified hEB popula-
tions, or singly picked blast colonies were directly replated onto irradiated (2000
cGy) OP9 stromal layers in 12- or 24-well gelatinized plates. OP9 cells (ATCC,
Manassas, VA) were maintained as described previously.36 OP9 differentiation
medium consisted of SFEM (StemCell Technologies), supplemented with 15%
fetal calf serum (FCS; StemCell Technologies), 50 g/mL ascorbic acid
(Sigma-Aldrich), 1% EX-CYTE, 0.5% insulin/transferrin/selenium (Invitrogen),
and penicillin/streptomycin (Sigma-Aldrich). OP9 media were supplemented
with human GFs. For erythromyeloid differentiation, we included Flt3 ligand (20
ng/mL), TPO (20 ng/mL), SCF (20 ng/mL), IL-3 (20 ng/mL), IL-6 (20 ng/mL),
G-CSF (20 ng/mL), GM-CSF (20 ng/mL), and EPO (2U/mL). For B-NK
lymphoid differentiation, we included Flt3 ligand (20 ng/mL), TPO (20 ng/mL),
SCF (20 ng/mL), IL-3 (20 ng/mL), IL-6 (20 ng/mL), IL-7 (20 ng/mL), IL-15 (10
ng/mL), and IL-2 (5 ng/mL) for the first week, followed by Flt3L
(50 ng/mL) IL-4 (20 ng/mL), IL-6 (20 ng/mL), IL-7 (20 ng/mL), IGF-I
(20 ng/mL), IL-15 (20 ng/mL), and IL-2 (5 ng/mL) in subsequent weeks.All OP9
differentiation cultures were fed by hemidepletion with fresh medium and GFs
twice per week for 3 weeks. Aliquots of expanded cell populations were
enumerated and evaluated by FACS analysis at weekly intervals. RAS peptides
or specific inhibitors were added directly into BL-CFC or hEB differentiation
media, as described in the text, and included angiotensin II peptide (Sigma-
Aldrich), Captopril (Calbiochem), losartan (AztraZeneca), and PD 123-319
(Sigma-Aldrich). Enzymatic ACE activity was determined from cell culture
supernatants using a colorimetric assay kit (ALPCO Diagnostics, Salem, NH),
according to the manufacturer’s instructions.
Results
Primitive and definitive erythromyelopoiesis from hEB cells
differentiated in SF conditions resembles that of the human
yolk sac
In preliminary experiments, we found that the minimal GF
combination of BMP4, VEGF, and FGF2/heparan sulfate (men-
tioned hereafter as BVF2H) was both necessary and sufficient for
inducing YS-like primitive and definitive hematopoiesis from hEB
differentiated in SF conditions (see Figure S1A-E for extensive
details). This minimal combination replaced the need for FCS to
induce hematopoietic differentiation and was used in subsequent
experiments aimed at expanding hEB-derived hemangioblasts. We
evaluated the frequency of hematopoietic progenitors generated
from SF BVF2H-supplemented hEB cultures by measuring the
hematopoietic CFC activity of disaggregated day 3 to day 15 hEBs
in SF methylcellulose cultures. These conditions produced
dramatically improved frequencies of primitive and definitive
hematopoietic colonies (Figure S1A), yet with morphologies
identical to those previously obtained in the presence of
serum24 (Figure S1B,C).
It is noteworthy that although hEB-derived erythroid colo-
nies scored as “definitive” expressed adult HbA chains, the
amount was considerably less than that from control CB-derived
erythroid colonies (30% vs 90% -globin expression,
Figure S1B). In addition, whereas CB-derived colonies ex-
pressed few embryonic ε-globin chains, hEB-derived definitive
colonies continued to express significant amounts of ε chains
(30%), suggesting that they are developmentally more primi-
tive than those derived from CB. Analysis of mixed erythro-
myeloid colonies from early (day 9) or later (day 14) hEB
(Figure S1C), similarly revealed an ε and  globin expression
pattern that was developmentally more primitive than that of
CB-derived CFU-GEMM colonies. Taken together, the coexpres-
sion of embryonic, fetal, and adult hemoglobin chains in
hEB-derived erythroid or mixed erythromyeloid colonies sug-
gested that hEB colonies scored as “definitive” are more similar
to the late yolk sac-early fetal liver erythropoietic developmen-
tal stage (ie, 6-8 weeks) than to adult-type definitive progeni-
tors, which would be characterized by minimal embryonic
hemoglobin synthesis, and predominant HbF and HbA expres-
sions.5,6 Moreover, these results are consistent with a previously
proposed model of hemoglobin switching in which
embryonic3 fetal3 adult globin transition is a time-depen-
dent process that occurs clonally rather than in separate
erythroid cell lineages.10
Thrombopoietin synergizes with mesodermal morphogens to
stimulate the clonal development of multilineage ACE blast
colonies
Our original studies on hESC differentiation in the presence of
serum predicted the emergence of a common hemangioblastic
progenitor preceding 2 waves of primitive and definitive
hematopoieses between days 4 and 10 of hEB differentiation.25
To elucidate the identity of this progenitor in a clonal manner,
and to characterize the factors and regulatory mechanisms
required for its expansion, we devised a completely serum-free,
quantitative blast colony-forming cell (BL-CFC) assay. In
designing this assay, we sought to avoid the use of FCS and
conditioned media (which contain undefined factors), as has
commonly been used in classic murine as well as in recently
described human hemangioblast assays.28,37
We tested a broad array of GFs known to stimulate expansion
of murine BL-CFC (eg, BMP4, VEGF, FGF2/heparin, SCF,
TPO, EPO, and IL-6) for their ability to generate human blast
colonies. Single-cell suspensions from day 2 to 14 hEB cells
(first differentiated in SF medium supplemented with BVF2H)
were tested for clonogenic blast colony expansion in SF
methylcellulose medium, in the presence of these GFs. With the
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same minimal combination of GFs used to differentiate hEB
(BVF2H), loosely packed blast colonies of cells with large
nuclei proliferated rapidly in SF methylcellulose, and reached
their full size (100 cells/colony) in 5 to 6 days (Figure 1A).
Their morphologies were easily distinguished from that of
secondary hEB colonies that had tighter, more heterogeneous
Figure 1. Phenotype of ACE  blast colonies generated in SF conditions. (A) Typical morphology of a blast colony with loosely packed cells generated from day 7 (line H1)
hEB differentiated in BVF2H; 5-6 days post-hEB cell plating. (B) Quantitative RT-PCR expression profiles: day 9 hEB blasts were expanded with 50 ng/mL TPO alone (T),
50 ng/mL each of SCF, BMP4, FGF2/heparin, TPO (SBF  T), 50 ng/mL each of SCF, BMP4, FGF2/heparin, VEGF (SBF  V), or 50 ng/mL each of SCF, BMP4,
FGF2/heparin, TPO, and VEGF (SBF  T  V). Blast colonies (10-15) from each GF condition were plucked from methylcellulose, pooled for RNA harvest, and analyzed for
expression of indicated transcripts by qRT-PCR, using the 2

T method25 (see Document S1). Shown are the relative, normalized expressions of CDX4, SCL, VWF,
VE-cadherin, TIE-2, GATA1, PECAM1, and KDR/flk1 compared with expressions in control, undifferentiated day 9 hEB cells. qRT-PCR products were verified to be specifically
amplified by agarose gel electrophoresis at linear ranges of amplification for the indicated conditions (data not shown). (C) FACS analysis of pooled (8-10) blast colonies from
day 7 hEB cells revealed abundant expression of ACE/BB9, CD164, CD41a, and CD43, and minor amounts of CD34, KDR, and CD45. BL-CFC activity is contained entirely
within BB9 hEB cell fractions. (D) Single cell suspensions from a representative sorting experiment: day 8 hEB (presorted hEB; hESC lines H1 and H9) were FACS-purified
into BB9 or BB9 sorted populations as described under “Methods.” (E) Eight to 15 	 104 viable, purified day 8 hEB cells, or 15 	 104 viable, presorted total day 8 hEB cells
from lines H1 or H9 (differentiated as described in Document S1) were recultured in duplicate in SF methylcellulose containing 50 ng/mL each of BMP4, FGF2/heparin, TPO,
VEGF, and IL-6. Blast colonies generated per viable, sorted hEB cells plated were enumerated after 4 to 5 days.
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arrangements (not shown). Addition of SCF, IL-6, Flt-3 ligand,
and EPO to the baseline GF combination of BVF2H did not
significantly increase the frequency of blast colonies formed
during days 4 to 10 of hEB development, although EPO induced
more robust erythroid differentiation (data not shown). The
addition of TPO, however, had a dramatic effect on blast colony
generation from single hEB cells, and almost doubled the
BL-CFC frequency when added along with BVF2H or even
when added alone (Figure S1D). This GF combination was
potent in generating blast colonies from at least three hESC lines
tested; day 8 hEB contained 2578.7 ( 205; H1; WA01), 10 570
( 495.3; H9; WA09), and 5823.9 ( 1520; ES03) BL-CFC per
million cells plated (Figure 1E and data not shown).
Blast cell colonies that had fully matured ( 6 days old) from
single (days 4-10) hEB cells were pooled and analyzed by FACS
and qRT-PCR for expression of markers of both hematopoietic and
endothelial cell lineages (Figure 1B). Regardless of the GF
combination used (GFs with or without TPO or TPO alone), blast
colonies all exhibited comparable expression profiles of key
hematoendothelial transcripts (eg, CDX4, SCL, von Willebrand
factor [VWF], VE-cadherin, TIE-2, GATA1, CD31 [PECAM1], and
KDR). In general, these transcripts were all overexpressed in blasts,
relative to undifferentiated hEB (except for CDX4). Furthermore,
FACS analysis of mature blast colonies demonstrated robust
surface expressions of CD164 (hematoendothelial cell lineage),
CD43 (embryonic panhematopoietic cell marker),38,39 and CD41
(embryonic hematopoietic-megakaryocytic cell marker) and weaker
expressions of CD34, KDR (hemato-endothelial progenitor mark-
ers), and CD45 (adult-type panhematopoietic cell marker).
Most importantly, we tested blast colonies for expression of the
BB9/ACE antigen, which we recently described as uniquely
typifying the emergence of human embryonic/fetal hematopoietic
progenitors. Indeed, mature blast colonies expressed abundant
amounts of surface ACE (Figure 1C). This observation prompted
the questions as to whether (1) surface ACE also typifies undiffer-
entiated hemangioblast colony-forming hEB cells (BL-CFC) that
presumptively give rise to blast colonies directly, and (2) whether
ACE-catalyzed angiotensin II peptide production plays a regula-
tory role in blast differentiation and/or expansion.
A single ACE  hemangioblast is a common progenitor for
2 waves of hEB-derived YS-like primitive and definitive
hematopoieses
In murine embryoid bodies, KDR/flk-1 cells include all BL-
CFC,40 whereas in hEB, BL-CFC were described in both KDR
and KDR fractions.28 Furthermore, KDR cells represent a large
percentage of cells (10-40%) during days 5-10 of hEB differentia-
tion (Figure S2A,B). To test the hypothesis that ACE expression
serves as a more reliable marker for BL-CFC than KDR/flk-1, we
sorted hEB cells into BB9 and BB9 fractions (Figure 1D).
Purified cells were recultured in SF methylcellulose along with our
optimized hemangioblast GFs (BVF2H  TPO  IL-6) and blast
colonies enumerated as above. This experiment revealed that
BL-CFC activity resides entirely within the BB9/ACE hEB cell
population (at a frequency of3% for day 9 hEB cells; Figure 1E).
To link expression of ACE, blast colony emergence, and onset
of primitive and definitive hematopoieses during hEB differentia-
tion, surface expressions of the hematoendothelial cell markers
ACE, CD34, CD31, CD43, CD45, CD41, and CD164 were
simultaneously evaluated in the same hEB cells used for CFC
assays between 3 and 20 days of differentiation (Figure 2). This
analysis revealed a unique developmental sequence that began with
Figure 2. Differentiation kinetics and surface phenotypes of clonogenic progeni-
tors of hEB-derived primitive and definitive hematopoieses. Line H1 hEB were
differentiated in SF medium and BVF2H for 3-20 days, as described under “Methods.”
hEB cells at different time points were evaluated for global gene expressions (A) by
DNA microarray (Agilent) analysis (see Table S2 for full list), surface marker
expression (E), or recultured at indicated time points in CFC assays (B-D). Replicate
CFC assay results represent the average, normalized (per 106 single, viable hEB
cells plated), for independent experiments done at least 3 times, with all standard
deviations less than 5%-10%). (A) Mesoderm marker Brachyury and hemangioblast-
associated (SCL/TAL1, RUNX1, GATA2) genes during days 0-10 of hEB differentia-
tion are selectively shown. (B) The kinetics of formation of BL-CFC, (C) MHE clusters,
mixed primitive  definitive erythro-myelopoietic colonies (MIXED) colonies, (D)
primitive erythropoietic (PRIM ERYTH), and definitive erythropoietic (DEF ERYTH)
CFU are shown during days 3-20 of hEB differentiation. Purple vertical dashed line
emphasizes that the initiation and pattern of blast colony formation (starting at day 5
of hEB differentiation) which correlates simultaneously with the onset of ACE/BB9
and CD34 hEB expression and also the emergence of primitive multipotent (MIXED),
also primitive erythroid (PRIM ERYTH) CFU (E). In contrast, CD34, CD164, CD31,
CD43, and CD41a hEB cell peak cell surface expressions patterns correlated more
with the emergence of definitive-type CFU from hEB at later time points (orange
dashed line).
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initially low expression of ACE on days 5 to 7 hEB (Figures 2E,
S2A) and correlated exactly with the expression (assessed by gene
microarray analysis) of transcription factors associated with hema-
topoietic cell genesis in differentiating hEB. All microarray data
have been deposited at Gene Expression Omnibus (GEO) under
accession number GSE12531. These events all directly followed
mesoderm-specific brachyury expression (Figures 2, S5). MHE
clusters (Figures 2C, S1C), which give rise to mesenchymal cells,
endothelium, and multipotent hematopoietic blasts,25 arose at 3 to
9 days of hEB differentiation. The emergence of these MHE
clusters roughly preceded ACE expression by hEB cells, BL-CFC
activity (Figure 2B), and mixed erythromyeloid CFC waves
(Figure 2C), which peaked during days 5 to 10 of hEB differentia-
tion. Furthermore, BL-CFC activity was correlated exactly with the
onset of expression of factors associated with hemangioblast
genesis including SCL/TAL1, RUNX1, and GATA2 (Figure 2A).
These waves of activity were followed by 2 waves of primitive
(days 6-12) and definitive (days 10-20) erythropoieses (Figure 2D).
It is noteworthy that although ACE expression by hEB cells rose in
parallel with primitive hematopoiesis, it peaked earlier than that of
the hematoendothelial cell marker CD34 (Figure 2E), which was
better correlated with expressions of CD31, CD164, CD43, CD41,
and CD45 (Figure 2E). Peak expression of all these latter markers
was also more closely correlated with definitive-type erythromyelo-
poiesis during days 10 to 20 of hEB differentiation (Figure 2D).
To confirm the full differentiation potential of ACE blast
colonies, individual ones derived from day 4 to 10 hEB cells were
plucked from methylcellulose, disaggregated, and (secondarily)
recultured onto fibronectin-coated wells containing SF methylcellu-
lose medium supplemented with a broad mixture of hemato-
endothelial GFs. The hemato-endothelial cell replating potential of
blast colonies was notably considerably improved when IL-6 was
included during blast colony expansion (Figure 3A). Under these
conditions, individual colony cells readily adhered to fibronectin,
and rapidly differentiated into multiple (2-10) secondary colonies
of round, hemoglobinizing, hematopoietic cells intermixed with
adherent, elongated endothelioid cells (Figure 3B). Cytospin stains
of these hematopoietic cells revealed a mixed, primitive, erythromy-
elopoietic phenotype, dominated by large nucleated erythroblasts.
FACS analysis of these cells demonstrated an abundance of
glycophorin A (CD235a)-positive erythroid cells and the absence
of adult-type CD45 hematopoietic cells. Elongated, adherent cells
intermixed with hematopoietic cells were CD31, VE-cadherin,
Ulex europaeus agglutinin-binding, and readily took up acetylated
Dil-LDL, hence were likely endothelial cells (Figures 3B, S3B).
Thus, blast colonies recultured under SF clonogenic conditions
gave rise to YS-like hematoendothelial progeny. In addition, blasts
from early (eg, day 5) hEB cells generated an approximately 50:50
mixture of hematopoietic and endothelial cells (Figure 3B),
whereas those from later stages (day 9-10 hEB) produced less
robust endothelial differentiation (10%-20% of secondary colo-
nies), but more robust hematopoiesis (80%-90% of secondary
colonies). Thus, blasts gradually lost their bipotentiality between
days 5 and 10 of hEB differentiation, in a manner similar to that
described for murine blast colonies.41
To test definitive hematopoietic potential, individual blast
colonies were plucked and recultured onto OP9 stromal lay-
ers36,38,42 supplemented with erythromyeloid or NK-B lymphoid
human GFs. Singly picked blast colonies differentiated robustly
into glycophorin A erythroid and adult-type CD45 myeloid
cells but poorly into CD56CD45and CD19CD45 B-NK
lymphoid progeny (Figure 3C). CD45 myeloid cells also
coexpressed CD13 and CD15 (myeloid cell markers), and CD41
(megakaryocyte cell marker). Cytospin stains of these differen-
tiated cells revealed adult-type erythroid cells with occasional
enucleation, as well as granulocytes, macrophages, and rare
polyploid megakaryocytes. Hemoglobin analysis of CD71
cells from these OP9 cocultures demonstrated that, compared
with blasts differentiated in SF conditions, these erythroid cells
expressed less embryonic (ε) globin and more adult () globin
(Figure 3C). Nonetheless, the coexpression of embryonic ε
combined with low adult -globin synthesis demonstrated that
blast-derived erythroid cells from OP9 cocultures were less
mature developmentally than CB-derived erythroid cells (which
express high levels of -globin, and little ε-globin).
The clonal origin of blast colonies was evaluated more
rigorously with dose-response and “mixing” experiments, using
hESC lines constitutively expressing lentiviral constructs encod-
ing enhanced green fluorescent protein (GFP) or red fluorescent
protein (RFP). For dose response analysis, day 5 hEB cells from
normal (wild-type [WT]), GFP, or RFP H1 hESC lines were
cultured in the presence of hemangioblast GFs, as above at
increasing numbers, and assayed for BL-CFC activity. A linear
correlation with a slope approximating 1 was observed between
the number of blast colonies developing and the number of hEB
cells plated (Figure 4A), which suggested a single hEB cell-
single blast colony relationship. Likewise, in mixing experi-
ments with 50:50 mixtures of GFP and RFP hEB cells, blasts
and their hematoendothelial secondary progeny were always
either only GFP or only RFP, but never both GFP and RFP
(Figure 5B). These analyses strongly suggest that multipotent
blast colonies arise from single stem-progenitor cells, and are
not derived from 2 lineage-distinct hEB cells sticking together,
or possibly even joined by fusion events.
Taken together, these data demonstrate that hESC-derived
blood cells emerge from a clonogenic, ACE, common hemangio-
blastic stem-progenitor of 2 waves of YS-like primitive and
definitive hematopoiesis. They also predict that these hemangio-
blasts are likely derived from an earlier ACE mesodermal
progenitor. Finally, these data collectively underscore critical and
synergistic roles for the RAS axis, TPO/MPL, FGF, and BMP
signaling pathways in regulating the emergence of human
hematopoiesis.
ACE expression prospectively identifies all multipotent
progenitors of embryonic hematopoiesis
In the adult, ACE is expressed on the surface of a wide variety of
nonrenal cells, including differentiated endothelial and stromal
cells. Because hemangioblastic activity in our system was
contained entirely within a small subset (3%) of days 5 to 10
ACE hEB cells, we further characterized the surface and
molecular phenotype of this hEB population. Because a signifi-
cant portion of ACE/BB9 cells also coexpress KDR/flk-1 and
CD34 (Figure S2C), we delineated the hemangioblastic poten-
tial of ACE cells in the context of these better-characterized
hematoendothelial cell markers.
hEB cells were FACS-purified into BB9 and BB9 frac-
tions, and coexpression of various hematoendothelial cell
surface markers was evaluated (Figure S4A). The majority of
BB9 hEB cells at this stage coexpressed multiple hemato-
endothelial cell markers such as CD34, CD31, KDR/flk-1, and
CD164 but scarcely expressed the strictly hematopoietic cell
markers CD43, CD41, and CD45. Thus, BB9 cell populations
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display a “prehematopoietic” phenotype at this stage. A quanti-
tative qRT-PCR analysis revealed that, in contrast to BB9
populations, BB9 hEB cells express higher levels of factors
associated with embryonic hematopoiesis, including AML1
isoforms, C-MYB, SCL, GATA1, PU.1, and MPL (TPO receptor).
Furthermore, expression of genes associated with embryonic
hematopoiesis including CDX2, EpoR, FLT3, MLL, HOXB4,
LMO2, GATA2, AML1 isoforms, C-MYB, SCL, GATA1, PU.1,
and MPL was dramatically up-regulated in blast colonies
derived from BB9  hEB cells (Figure S4B).
Figure 3. Hematopoietic potential of ACE blast colonies. (A) Secondary colony replating efficiencies of individually picked blast colonies. Blast colonies from hESC Line
H1 day 9-10 hEB cells were generated, as described in “Methods,” in the presence of 50 ng/mL each of SCF, BMP4, FGF2/heparin  VEGF (SBFH  V), 50 ng/mL each of
SCF, BMP4, FGF2/heparin  TPO  VEGF (SBFH  T  V), or 50 ng/mL each of SCF, BMP4, FGF2/heparin  TPO  VEGF  IL-6 (SBFH  T  V  IL-6). The
percentage of individually picked blast colonies that formed secondary hematopoietic-only (H), or hematopoietic and endothelial (HE) colonies, for each condition is shown.
The addition of IL-6 did not increase the frequency of blast colony generation (data not shown) but greatly enhanced their secondary replating potential to aproximately 80%.
Shown is a representative experiment (done at least twice), with the number of single blast colonies evaluated per condition (n  11). Day 5-9 hEB-derived blast colonies were
individually plucked, and secondarily recultured (5-6 days after single hEB cell plating) into single wells on either (B) fibronectin-coated dishes containing SF methylcellulose
medium and GFs (SCF, BMP4, Flt3L, TPO, IGF-1, GCSF, GMCSF, IL-3, IL-6, EPO, VEGF), or (C) OP9 bone marrow stromal layers containing the same GFs, for definitive
hematopoietic differentiation. Day 5 hEB blast colonies secondarily recultured into SF conditions consistently resulted in simultaneous differentiation into primitive, YS-like
CD235a/CD45- erythro-myelopoietic (B, left panel and far right panels), and adherent endothelial cells that take up acetylated Dil-LDL (B, middle panel). Nuclei are stained blue
with DAPI. These erythroblasts express only  and , but not  hemoglobin chains (C; “SF,” middle panel). In contrast, single blast colonies recultured onto OP9 layers with
human lymphohematopoietic growth factors (EPO, SCF, Flt3L, TPO, IL-3, IL-6, G-CSF, GM-CSF, IL-2, IL-7, IL-15) produced definitive-type CD235a/CD45 erythromyelopoi-
etic differentiation (C, top left panel), with enucleating  hemoglobin-expressing erythrocytes (C, bottom left panel), definitive-type myeloid cells (C, top right panel,
CD13  CD15  CD45), and also NK-lymphoid (CD56  CD45) but scarce amounts of phenotypic B-lymphoid cells (CD19 CD45; C, bottom right panel).
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Various studies have demonstrated that CD34 and KDR/flk-1
may not comprehensively mark all primitive hematopoietic stem-
progenitor populations. Primitive hematopoietic progenitors, for
example, exist within both fetal and adult CD34 and CD34
populations in several species.43,44 Because significant portions of
purified BB9 hEB cells did not coexpress CD34 (Figure S4A), we
next tested the hematopoietic potential of both BB9CD34 and
BB9CD34 hEB cell fractions. Single, FACS-purified cells were
assayed for either primitive hematopoietic potential in SF heman-
gioblast CFC assays, (Figure 5A-D), or definitive-type hematopoi-
etic potential on OP9 stromal layers (Figure 5E,F). CFC assays at
day 9 and day 14 of hEB development revealed that clonogenic
multipotent hematopoietic progenitors are present in both
CD34BB9 and CD34BB9 fractions, but not within
CD34BB9 cells (Figures 1D and 5C). Interestingly, the majority
of multilineage colonies were present in CD34BB9, rather than
in CD34BB9 cell populations. Thus, BB9/ACE surface expres-
sion was more comprehensive in identifying hemangioblastic and
multipotent hematopoietic progenitors among hEB cells than was
CD34 expression alone. Similar experiments conducted with
FACS-purified KDRBB9 and KDRBB9/KDRBB9 day 5
hEB cells revealed that BB9/ACE is a more comprehensive marker
for identifying clonogenic hemangioblastic progenitors in hEB
cells than KDR expression alone (Figure S2C).
To test for the definitive hematopoietic potential of BB9
hEB cells, these sorted hEB populations were seeded onto OP9
stroma under erythromyeloid or NK-B lymphoid GF conditions.
Once again, CD34BB9 hEB cells exhibited more robust
multilineage definitive lymphohematopoietic potential than
CD34BB9 hEB cells (Figure 5E,F). Both populations, how-
ever, exhibited relatively poor B-lymphoid differentiation poten-
tial (data not shown) with CD45CD19lo putative B-lymphoid
lineage cells expressing RAG1 but scant surrogate light chains
(VpreB, 5) and C heavy chains, consistent with a pro-B
developmental stage. Nonetheless, BB9/ACE was the sole
marker necessary and sufficient for identifying the entire range
of YS-like primitive/definitive hematoendothelial progenitors
during human EB differentiation.
The renin-angiotensin axis regulates the expansion and
differentiation of human embryonic hemangioblasts
The validation of BB9/ACE as a positive marker of hESC-
derived hemangioblasts and multipotent progenitors strongly
Figure 4. A single hEB cell generates one blast
colony with bipotential hematoendothelial capacity.
(A) hEB cell dose response. To demonstrate that a single
hEB cell has hemangioblastic capacity, the linear correla-
tion of BL-CFC to the number of unfractionated Line H1
day 8 hEB plated was evaluated. Shown is the direct
linear relationship observed with a slope 1, which is
highly suggestive that each colony is derived from a
single colony-forming cell. hEB cells from H1 hESC
subclones transduced with lentiviral constructs express-
ing GFP or RFP demonstrated robust BL-CFC formation
comparable with the H1 parental line (WT), with a similar
linear correlation to numbers of cells plated. (B,C) GFP-
RFP hEB Mixing Experiments. To further rule out the
possibility that BL-CFC have apparent bipotentiality from
the possibility that 2 separately derived progenitors are
stuck or fused together, a 50:50 single-cell suspension
mixture of GFP-expressing and RFP-expressing day 9
hEB cells was prepared (B), and blast colonies (phase
image, “B” were expanded from this GFP-RFP mixture in
BVF2H  TPO  IL-6, as before. (C) Secondary colo-
nies from individually replated blast colonies (“B”) pro-
duced secondary endothelial colonies (“E”), hematopoi-
etic colonies (“H”), or mixed hematoendothelial (“HE”)
colonies. These secondary colonies were always GFP or
RFP-expressing under fluorescent microscopy, and there
were never colonies with both GFP and RFP expression
mixed together. This experiment (with n  24 picked
blast colonies replated) was repeated with similar results,
for a total of n  50 colonies evaluated.
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predicted that the RAS regulates human embryonic hematopoi-
esis. We examined this possibility by first probing the expres-
sion of critical components of the RAS axis on ACE hEB cells,
ACE hEB cells, and ACE blast colonies (Figure 6A,B). Blast
colonies with surface BB9/ACE expression had not only robust
enzymatic ACE activity (Figure 6B) but also expressed tran-
scripts for angiotensinogen. This essential precursor is catalyzed
by renin into angiotensin I (Ang I), which is subsequently
catalyzed by ACE into the bioactive peptide angiotensin II (Ang
II). It is noteworthy that BB9 but not BB9 hEB cells
Figure 5. Hematopoietic potential of purified BB9 and CD34 hEB populations. Line H1 day 9 hEB cell suspensions (presorted) were FACS-purified into
(A) CD34BB9, CD34BB9, and CD34BB9 fractions (postsort analysis of purified positive fractions shown in middle and right panels). (B-D) Sorted cells were cultured
onto duplicate fibronectin-coated dishes with SF methylcellulose and hemato-endothelial GFs, as described under “SF clonogenic assays for hematopoietic and
hemangioblastic colony-forming cells.” (B,C) single day 9 CD34BB9 and CD34BB9 (but not CD34BB9) hEB cells differentiated into hemangioblastic colonies of mixed
primitive erythromyeloid cells and adherent endothelioid cells (MIXED-HE), as well as primitive erythroid (EryP) colonies. Day 14 hEB similarly FACS-purified into these same
populations (D), generated more varied CFU including mixed hematoendothelial (MIXED-HE), primitive erythroid (EryP), definitive erythroid (CFU-e-d), and macrophage
(M-CFC) colonies. At both days 9 and 14, hematopoietic CFU progenitor activity was greater in CD34-BB9 than in CD34BB9 populations; at Day 14 this represented
approximately 6% of CD34BB9 cells, and approximately 10% of CD34BB9 cells. (E,F) Definitive hematopoietic differentiation of these same populations on OP9 stroma
with erythromyeloid GFs. Both CD34BB9 and CD34-BB9 (but not CD34BB9) fractions produced robust definitive hematopoietic potential, but CD235a/
CD45CD13CD15 definitive-type erythro-myeloid cells had a more robust proliferation in the CD34BB9 fraction.
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Figure 6. Blast colonies express RAS components that regulate their expansion and differentiation. (A) RNA was harvested from sorted hESC Line H1 day 9
BB9  hEB (BB9), day 9 BB9 hEB (BB9), day 9 blast colonies (Blasts), or control human umbilical vein endothelial cells (HUVECs). Expression was assayed for actin,
AGTR1, AGTR2, or angiotensinogen (AGTN) by qRT-PCR, as described in Document S1. Left panel demonstrates agarose gels of samples of PCR products (1/5 sample
loaded) at linear amplification ranges for assayed transcripts. In right panel are relative, actin-normalized quantitative comparisons; fold change expression differences indicate
levels of transcripts (calculated using the 2

T method) of pooled day 9 blast colonies, compared with expression levels from sorted day 9 BB9 hEB cells. (B) ACE enzymatic
activity (units per number cultured cells assayed; mean  SEM) was determined by colorimetric assay (in triplicate) from supernatants of pooled day 9 hEB blast colonies
(BLASTS), or control supernatants from HUVEC (which express high levels of surface BB9/ACE (data not shown). (C) hEB were differentiated for hematopoietic progenitors
(Figure S1A) in the presence or absence of specific RAS inhibitors. Captopril (100 M; ACE inhibitor), 100 M losartan (AGTR1 inhibitor), or 100 M PD 123-319 (AGTR2
inhibitor) were included starting at day 4 of hEB culture. Day 14 hEB cell suspensions were assayed in duplicate in CFC assays, as before. (D) BL-CFC assays from days 5 to 9
hEB were conducted in the presence of supplemental angiotensin II peptide (ANG II; 100 g/mL), captopril (100 M), losartan (100 M), or PD 123-319 (100 M). Shown is the
average of 2 independent experiments from day 9 hEB, with a similar pattern of results obtained with inhibitors in days 5 and 7 hEB BL-CFC assays (data not shown). (E,F)
Blast colonies generated from day 5 or day 9 hEB cells were expanded in the presence of No inhibitor (control), 100 M losartan, or 100 M PD 123-319, and replated for
secondary hematoendothelial CFC, as before. Although control blasts generated both hematopoietic and endothelial (HE) secondary progeny, the majority of blast colonies
from losartan-treated blasts regenerated (robust) hematopoietic-only (H) progeny, whereas the majority of PD 123-319–treated blasts generated primarily endothelial-only (E)
progeny. Shown panel F results are from blasts individually picked and replated blasts (n  20 per condition), with typical secondary colony morphologies shown in panel E.
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expressed angiotensin II type 1 receptor transcripts (AGTR1;
Figure 6A,B), but poor amounts of angiotensin II type 2 receptor
(AGTR2). Furthermore, AGTR2, which is normally rarely ex-
pressed in adult tissues, but abundant in the developing fe-
tus,45-47 was dramatically up-regulated ( 104-fold) during blast
colony expansion (Figures 6A, S5B). Thus, all the components
necessary for bioactive Ang II synthesis (angiotensinogen,
ACE), and Ang II signaling (AGTR1, AGTR2) were synthesized
by blast colonies (locally), apparently in an autocrine or
paracrine manner. Accordingly, addition of saturating concentra-
tions of exogenous Ang II peptide to BL-CFC assays did not
further influence the frequency of blast colony formation from
hEB cells (Figure 6D).
To ascertain whether either ACE function or AGTR1/AGTR2
signaling regulates hEB-derived hematopoiesis, we conducted
differentiation and BL-CFC assays in the presence of specific
inhibitors that block either synthesis or signaling of ANG II (Figure
6C-F). Differentiating hEB were treated with either an ACE
inhibitor (captopril), AGTR1 inhibitor (Losartan), or an AGTR2
inhibitor (PD 123-319; 1-[[4-(dimethylamino)-3-methylphenyl]-
methyl]-5-(diphenyl lacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-
c]pyridine-6-carboxylic acid ditrifluoroacetate). It is noteworthy
that inhibition of both AGTR2 and ACE severely reduced the
ability of day 14 hEB to generate hematopoietic CFC, thus
demonstrating a requirement of Ang II synthesis and/or
AGTR2 signaling in hematopoietic progenitor expansion from
earlier hEB cells (Figure 6C). We were surprised to find that
inhibition of AGTR1 signaling with losartan robustly stimulated
the expansion of hematopoietic CFU from day 14 hEB, including
an approximately 7- to 10-fold increase in mixed, multipotent
progenitors (Figure 6C).
To determine whether ACE or AGTR inhibitors act either
directly on hemangioblast expansion, or on more committed
progenitors, we included these blockers in BL-CFC assays (Figure
6D). Addition of captopril or the AGTR2 inhibitor PD 123-319 to
day 5-9 hEB directly inhibited the expansion of blast colonies,
whereas addition of the AGTR1 inhibitor losartan did not apprecia-
bly affect the frequency of blast formation at any time point. These
data strongly suggested that both the catalysis of angiotensin II
peptide by ACE, as well as its subsequent signaling via AGTR2
were both critical for blast colony proliferation. Replating of
individual inhibitor-treated blast colonies, however, revealed a
surprising finding. Although captopril and PD 123-319 dramati-
cally diminished the expansion of blasts, replated captopril or PD
123-319–treated blasts produced a predominantly endothelial prog-
eny, with poor hematopoietic differentiation. Conversely, losartan-
treated blasts produced a predominantly hematopoietic progeny,
with limited endothelial differentiation (Figure 6E,F). Because the
2 Ang II receptors generally antagonize each other’s functions,48
unopposed AGTR2 signaling consequent to losartan-AGTR1 inhi-
bition seemed to direct and augment blast differentiation toward
multilineage hematopoietic progeny. Conversely, unopposed
AGTR1 signaling in PD 123-319-AGTR2-inhibited blasts, al-
though fewer in number, produced predominantly endothelial cells
in secondary cultures (Figure 6E,F).
Taken together, these data suggest that hemangioblast differen-
tiation into either hematopoietic or endothelial progeny is differen-
tially regulated via Ang II signaling through AGTR1 and AGTR2.
These data thus reveal how human embryonic hematoendothelio-
genesis from hemangioblasts may be regulated in local stem cell
niches where angiotensin peptides are normally synthesized.
Discussion
Because it begins as early as the third week of gestation, the
developmental biology of human blood cell emergence currently
remains almost inaccessible to investigation. We now outline a
surrogate experimental system that recapitulates the step-wise
developmental origins of human yolk sac hematopoiesis using
differentiating hESC. Scarce characterizations of YS tissue at
approximately 2 to 3 weeks of human gestation2,3,49 have demon-
strated the presence of mesodermal clusters (blood islands) that
differentiate into comingled CD34 endothelium and blood cells,
inferring the existence of a putative hemangioblast at the origin of
both. The existence of a human hemangioblast, however, has been
impossible to demonstrate directly and in a clonal manner, as it has
been in the mouse embryo.50
Our work herein characterizes a clonogenic, hESC-derived
hemangioblast that expresses surface angiotensin-converting en-
zyme (CD143) and initiates both primitive and definitive YS-like
hematopoieses (Figure 7A). The ontogenic pattern of development
of this novel human stem-progenitor cell into primitive and
definitive YS lineages seems to be almost identical to that of
hemangioblasts generated from murine embryoid bodies37 and
murine embryos.50 Moreover, our hEB system seems to recreate
hematopoietic events in vitro that normally occur during the first
weeks of human development and with a remarkably parallel
timeline (Figure 7B). The hESC lines (H1;WA01, H9;WA09)
primarily used in these studies were derived from the inner cell
masses of an approximately 6-day-old human blastocyst51 and were
maintained in a pluripotent, undifferentiated state before hematopoi-
etic hEB differentiation. During normal gestation, human YS
development directly follows formation of the primitive streak (PS;
Figure 7B) and secondary YS extraembryonic mesoderm layers (2°
YS; Figure 7B) at days 12-13. The formation of primordial blood
islands (YS blood islands; Figure 7B) first occurs at days 14 to 16,
with subsequent generation of primitive erythromyelopoietic cell
lines starting after 18 to 20 days.3,49 Because in vitro hEB
differentiation is an experimental surrogate for postimplantation
developmental events, the normal human YS developmental mile-
stones are indeed remarkably congruent to hematopoietic hEB
differentiation. In murine embryos, hemangioblasts first appear in
the posterior region of the primitive streak.50 MHE clusters and
ACE BL-CFC similarly arise in our system at a corrected
gestational timeline of approximately 12 to 13 days (6 days of
blastocyst age  days 6-7 of hEB differentiation), which is when
the human primitive streak first develops. Subsequently, primitive
erythropoiesis arises at a corrected timeline of approximately 14 to
16 days (6 days of blastocyst age  8-10 days of hEB differentia-
tion), which is the milestone for YS blood island generation.
Finally, definitive erythromyelopoiesis arises in our system at a
corrected timeline of more than 18 to 20 days (6 days of blastocyst
age  12-20 days of hEB differentiation), when similar events
occur in the human YS, before the onset of fetal circulation at
approximately 21 days.
The most compelling aspect of our results is that BB9/ACE
expression prospectively identifies hemangioblasts derived from
hEB. ACE hemangioblasts are found within not only CD34, but
also (and even more robustly) among CD34 hEB cells. This result
is in agreement with our immunohistochemical analysis of the
human AGM, which shows the migration of ACECD34CD45
mesoderm cells from the splanchnopleura toward the dorsal aorta
before the onset of intraembryonic hematopoiesis.34 Although it is
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well known that HSC exist in CD34 fetal and adult blood in both
mouse and humans,43,44,52 it remains to be seen whether ACE
expression will represent a more comprehensive prospective marker
than CD34 alone for identifying primitive human HSC.
Most importantly, our studies suggest a role for the renin-
angiotensin axis in directly regulating the genesis of human
embryonic angio-hematopoiesis. Captopril inhibition of ACE enzy-
matic activity, severely inhibited human hemangioblast colony
expansion, similar to effects described on progenitors in murine
bone marrow cultures.53 In addition, the decision to differentiate
into either endothelial or hematopoietic progenitors was directly
determined via differential signaling through the 2 main angioten-
sin II receptors, which are expressed on human hemangioblasts.
Although the RAS was originally thought to be restricted to
regulating cardiovascular functions, ACE and its main enzymatic
product, the angiotensin II peptide (Ang II), have recently emerged
as important determinants of angiogenesis, inflammation, tumor
progression, and hematopoiesis.54-56 The effects of the bioactive
Ang II peptide, are mediated via specific binding and signaling
through its 2 main receptors, AGTR1 and AGTR2. ACE inhibitors
and angiotensin receptor blockers are widely used clinically and
well tolerated, although with sporadic reports of decreases in
hematocrit or even bone marrow aplasia. Regulatory effects of the
RAS on hematopoiesis have amply been reported. ACE, angio-
tensinogen, and renin are all expressed during blood island
differentiation in the chick YS, and ACE inhibitors dramatically
reduce chick primitive erythroid cell development. Our studies are
the first, to our knowledge, that demonstrate and extend similar
effects on human primitive hematopoiesis. Moreover, ACE and
Ang II receptor inhibition are associated with improved HSC
recovery after chemotherapy induction, an effect that was origi-
nally interpreted to be due to the tetrapeptide AcSKDP, a negative
regulator of hematopoietic proliferation, that is cleaved into its
inactive form by ACE.57,58 Because the Ang II peptide is a direct
mitogen for both human erythroid and CD34 hematopoietic cell
progenitors59,60 and specific AGTR1 inhibition has been reported to
favor hematopoietic progenitor expansion through an unknown
mechanism,61 AcSDKP is unlikely to be an important mediator of
RAS function in hematopoietic progenitors. The mechanism of
ACE regulation on hemangioblast differentiation, although cur-
rently unknown, is more likely related to direct Ang II receptor
signaling but may be complicated by involvement of bradykinin,
Figure 7. Scheme for the ontogeny of in vitro, hESC-
derived hemangioblasts (A), and its congruence with
the developmental timeline of normal human YS
development (B). PC, progenitor cell; MESO, meso-
derm progenitor; BL-CFC, hemangioblast progenitor;
PRIM, primitive hematopoiesis; DEF, definitive (YS-like)
hematopoiesis; PS, primitive streak; 2° YS, secondary
yolk sac.
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another peptide cleaved by ACE into an inactive form that also has
important proangiogenic effects.56
Our studies further suggest that manipulation of AGTR2
signaling is an important strategy for expanding multipotent
hematopoietic progenitors in general. In humans and rodents,
AGTR2 is transiently expressed during fetal development but
scarcely expressed in adults.45,46 Components of the renin-
angiotensin axis are locally expressed in the YS, liver, kidney,
embryonic aorta, and retina/choroid regions, which are all impor-
tant sites of emerging angiohematopoiesis. In adults, the effects of
Ang II (eg in the cardiovascular system) are primarily mediated by
the G-protein–coupled AGTR1 complex. In our studies, AGTR2
function was necessary for expansion of hemangioblast colonies
into multipotent hematopoietic progenitors, and its inhibition with
PD 123-319 completely abolished hematopoietic differentiation,
while imposing an almost exclusive endothelial fate on hemangio-
blast colonies. Conversely, specific inhibition of AGTR1 signaling
with losartan dramatically augmented differentiation into multipo-
tent hematopoietic progenitors, perhaps by allowing unopposed
AGTR2 signaling by Ang II. Because the AGTR2 receptor is
known to antagonize AGTR1 directly,48,61 or compete for Ang II
binding, these results may implicate a mechanism by which
emerging hemangioblasts in the YS or AGM are directed by the
stem cell niche in patterning the generation of hematopoietic stem
cells or alternatively the construction of vascular-endothelial
networks. Although the mechanism involved is currently unknown,
AGTR1/AGTR2-mediated stem cell proliferation may be a gener-
alized phenomenon, since AGTR1 inhibition by losartan is re-
ported to increase skeletal muscle regeneration via TGF- signal-
ing.62 Indeed, the importance of autocrine and paracrine regulation
by the RAS axis is well recognized in the development of multiple
fetal organs, and both ACE and AGTR1 receptor blockers are
known teratogens. AGTR2 signaling, for example, plays central
roles in regulating cellular growth or apoptosis during vascular and
neural development.47,63 In addition, mutations of AGTR2 exist in
patients with severe mental retardation and autism,64 confirming a
critical role for neural development. Pathologic effects on other
organ systems (eg, the hematopoietic system) in these patients were
not described.
In summary, we show that human angio-hematopoiesis initiates
from an ACE hemangioblastic progenitor of primitive and
(limited) definitive hematopoiesis. Strikingly, the developmental
timeline of normal YS development appears parallel to our hEB
differentiation events, suggesting an inherently programmed series
of genetic steps that are invariant in both hESC and developing
human embryos. Finally, we describe a previously unrecognized
role of the angiotensin receptors in regulating human hemangio-
blast differentiation that should enlighten our understanding of
HSC expansion in general, as well as guide future strategies for
directing and efficiently expanding hESC-derived hemangioblasts
for vascular and hematologic therapies.
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